Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 4, 2010, Pages 721-728

  Sato, Yasushi ^a   Takayama, Tetsuji ^b   Sagawa, Tamotsu ^a   Takahashi, Yasuo ^c   Ohnuma, Hiroyuki ^c   Okubo, Syunichi ^c   Shintani, Naoaki ^c   Tanaka, Shingo ^a   Kida, Masaya ^d   Sato, Yasuhiro ^e   Ohta, Hidetoshi ^e   Miyanishi, Koji ^a   Sato, Tsutomu ^a   Takimoto, Rishu ^a   Kobune, Masayoshi ^a   Yamaguchi, Koji ^a   Hirata, Koichi ^a   Niitsu, Yoshiro ^a   Kato, Junji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d Chitose City Hospital   (Japan)

^e Oji General Hospital   (Japan)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; GRANULOCYTE COLONY STIMULATING FACTOR; OXONIC ACID; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRECTOMY; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARIECTOMY; OVARY METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SEX RATIO; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; VOMITING; CANCER GROWTH; DRUG EFFICACY; DRUG RESPONSE; HUMAN TISSUE; INOPERABLE CANCER; METASTASIS; PROGRESSION FREE SURVIVAL; STOMACH ADENOCARCINOMA; SURVIVAL TIME; CANCER INVASION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEUTROPENIA; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 77955910312     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1215-2     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Inoue M, Tsugane S (2005) Epidemiology of gastric cancer in Japan. Postgrad Med J 81:419-424
3. Alberts SR, Cervantes A, van de Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14 (Suppl 2): ii31-ii36
4. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10 (Suppl 3):49-58
5. Yoshida M, Ohtsu A, Boku N et al (2004) Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the japan clinical oncology group (JCOG) study. Jpn J Clin Oncol 34:654-659
6. Shah MA, Schwartz GK (2004) Treatment of metastatic esophagus and gastric cancer. Semin Oncol 31:574-587
7. Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology group study (JCOG9205). J Clin Oncol 21:54-59
8. Dickson JL, Cunningham D (2004) Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 16:255-263
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
10. Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-1069
11. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
12. Ajani JA, Rodriquez W, Bodoky G et al (2009) Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. ASCO Annual Meeting Proceedings. J Clin Oncol 27:15s (abstr 4511)
13. Einzig AI, Neuberg D, Remick SC et al (1996) Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol 13:87-93
14. Sulkes A, Smyth J, Sessa C, EORTC Early Clinical Trials Group et al (1994) Docetaxel (taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70:380-383
15. Roth AD, Maibach R, Martinelli G, Swiss group for clinical cancer research (SAKK), and the European institute of oncology (EIO) et al (2000) Docetaxel (taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301-306
16. Thuss-Patience PC, Kretzschmar A, Repp M et al (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23:494-501
17. Yamaguchi K, Shimamura T, Hyodo I et al (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803-1808
18. Takayama T, Sato Y, Sagawa T et al (2007) Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 97:851-856
19. Nishi M, Omori Y, Miwa Y (1999) Response assessment of chemotherapy and radiotherapy for gastric carcinoma part IV. Kanehara Shuppan, Tokyo
20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92:205-216
21. Kim NK, Park YS, Heo DS et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818
22. Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the european organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol 18:2648-2657
23. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
24. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
25. Chun JH, Kim HK, Lee JS et al (2005) Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28:188-194
26. Boku N, Ohtsu A, Shimada Y et al (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323
27. Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457
28. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 20:1435-1442
29. Koizumi W, Tanabe S, Saigenji K et al (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207-2212
30. Taguchi T, Sakata Y, Kanamaru R et al (1998) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese cooperative study group trial (group A). Gan To Kagaku Ryoho 25:1915-1924
31. Mai M, Sakata Y, Kanamaru R et al (1999) A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan To Kagaku Ryoho 26:487-496
32. Yoshida K, Ninomiya M, Takakura N et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-3407
33. Ajani JA, Fodor MB, Tjulandin SA et al (2005) Phase II multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667
34. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395-2403
35. Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43:256-264
36. Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996-2004 (Pubitemid 34413593)
37. De Vita F, Orditura M, Matano E et al (2005) A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92:1644-1649
38. Nakajima T, Ota K, Ishihara S et al (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203-208
39. Gallardo-Rincon D, Onate-Ocana LF, Calderillo-Ruiz G (2000) Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 7:45-50
40. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991-4997
41. van Groeningen CJ, Godefridus J, Peters J et al (2000) Phase I clinical and pharmacokinetic study of S-1 in advanced solid tumors. J Clin Oncol 18:2772-2779
42. Ajani JA, Faust J, Ikeda K et al (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957-6965
43. Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221-231
44. Sym SJ, Chang HM, Ryu MH et al. (2009) Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 26 (Epub ahead of print)